Current status of molecular biomarkers in endometrial cancer (Q38234228)

31 August 2017

title

Current status of molecular biomarkers in endometrial cancer (English)

1 reference

31 August 2017

0 references

H M J Werner

1 reference

31 August 2017

H B Salvesen

series ordinal

1 reference

31 August 2017

publication date

1 September 2014

1 reference

31 August 2017

published in

Current Oncology Reports

1 reference

31 August 2017

1 reference

31 August 2017

1 reference

31 August 2017

page(s)

403

1 reference

Contemporary management of endometrial cancer

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Obesity and gynecologic cancer etiology and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Trends in endometrial cancer incidence rates in the United States, 1999-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Markers for individualised therapy in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Two pathogenetic types of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Emerging therapeutic targets in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Improved survival related to changes in endometrial cancer treatment, a 30-year population based perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Diagnostic accuracy of preoperative tests for lymph node status in endometrial cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Does the use of the 2009 FIGO classification of endometrial cancer impact on indications of the sentinel node biopsy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Stathmin is superior to AKT and phospho‐AKT staining for the detection of phosphoinositide 3‐kinase activation and aggressive endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Value of Preoperative CA 125 Level in the Management of Uterine Cancer and Prediction of Clinical Outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Advancements in the use of blood tests for cancer screening in women at high risk for endometrial and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Three-dimensional ultrasound for assessing women with gynecological cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Staging of endometrial carcinomas with MRI using traditional and novel MRI techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer - a multicenter prospective comparative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Molecular pathology of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Aneuploidy predicts outcome in patients with endometrial carcinoma and is related to lack of CDH13 hypermethylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma: dNA aneuploidy identifies high-risk cases among the so-called 'low-risk' patients with well and moderately differentiated tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Clinical value of DNA content assessment in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

PIK3R1 (p85α) Is Somatically Mutated at High Frequency in Primary Endometrial Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Integrated genomic characterization of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Clinical significance of microsatellite instability in endometrial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Prognostic impact of EMT (epithelial-mesenchymal-transition)-related protein expression in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Drug-sensitive FGFR2 mutations in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Does the Loss of ARID1A (BAF-250a) Expression in Endometrial Clear Cell Carcinomas Have Any Clinicopathologic Significance? A Pilot Assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Serum HE4 as a prognostic marker in endometrial cancer--a population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

The utility of serum CA‐125 in predicting extra‐uterine disease in apparent early‐stage endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

HE4 is an independent prognostic marker in endometrial cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Economics of new oncology drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Systemic therapy for recurrent endometrial cancer: a review of North American trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Hormone therapy in advanced and recurrent endometrial cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Intratumor heterogeneity: evolution through space and time

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Implementing personalized cancer genomics in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Companion biomarkers: paving the pathway to personalized treatment for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Reporting recommendations for tumor marker prognostic studies (REMARK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Cancer Systems Biology: a peek into the future of patient care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Designing transformative clinical trials in the cancer genome era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Development and use of integral assays in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

Translating cancer research into targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0403-3

HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients

21 January 2018

1 reference

12 December 2020

Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas

1 reference

12 December 2020

Elevated Plasma Growth Differentiation Factor-15 Correlates with Lymph Node Metastases and Poor Survival in Endometrial Cancer

1 reference

12 December 2020

Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma

1 reference

12 December 2020

ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas

1 reference

12 December 2020

Prognostic Value of E-Cadherin Expression and CDH1 Promoter Methylation in Patients With Endometrial Carcinoma

1 reference

12 December 2020

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

1 reference

12 December 2020

Evolution in Endometrial Cancer: Evidence From an Immunohistochemical Study

1 reference

12 December 2020

PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics.

1 reference

12 December 2020

Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium

1 reference

12 December 2020

Magnetic resonance imaging performs better than endocervical curettage for preoperative prediction of cervical stromal invasion in endometrial carcinomas

1 reference

12 December 2020

Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma

1 reference

12 December 2020

Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer

1 reference

12 December 2020

The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways

1 reference

12 December 2020

Lymphadenectomy for the management of endometrial cancer

1 reference

12 December 2020

Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting

1 reference

12 December 2020

Endometrial cancer: can nodal status be predicted with curettage?

1 reference

12 December 2020

Para-aortic lymphadenectomy in the management of preoperative grade 1 endometrial cancer confined to the uterine corpus

1 reference

12 December 2020

10.1007/S11912-014-0403-3

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1036049372

0 references

OpenCitations bibliographic resource ID

579

0 references

1 reference